West Pharmaceutical Services, Inc. (NYSE:WST) Given Average Rating of “Buy” by Analysts

Shares of West Pharmaceutical Services, Inc. (NYSE:WST) have earned an average rating of “Buy” from the thirteen analysts that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $314.5556.

A number of research analysts recently issued reports on the stock. Morgan Stanley started coverage on shares of West Pharmaceutical Services in a research report on Monday, December 1st. They set an “equal weight” rating and a $285.00 target price for the company. Wall Street Zen raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Saturday, December 20th. Barclays reduced their price objective on West Pharmaceutical Services from $325.00 to $265.00 and set an “equal weight” rating for the company in a research note on Friday, February 13th. Jefferies Financial Group reissued a “buy” rating and issued a $295.00 price objective on shares of West Pharmaceutical Services in a report on Tuesday, February 10th. Finally, UBS Group reaffirmed a “buy” rating and set a $340.00 target price on shares of West Pharmaceutical Services in a report on Friday, February 13th.

Hedge Funds Weigh In On West Pharmaceutical Services

Several large investors have recently made changes to their positions in the company. Generation Investment Management LLP acquired a new stake in shares of West Pharmaceutical Services in the second quarter valued at about $255,072,000. Norges Bank acquired a new position in shares of West Pharmaceutical Services during the 4th quarter worth about $272,041,000. Artisan Partners Limited Partnership raised its position in shares of West Pharmaceutical Services by 22.2% during the 3rd quarter. Artisan Partners Limited Partnership now owns 2,770,920 shares of the medical instruments supplier’s stock worth $726,895,000 after purchasing an additional 503,601 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in West Pharmaceutical Services by 67.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,174,962 shares of the medical instruments supplier’s stock valued at $323,280,000 after buying an additional 473,547 shares in the last quarter. Finally, Steadfast Capital Management LP acquired a new stake in West Pharmaceutical Services in the 3rd quarter worth about $123,667,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Zacks Research raised several near‑term and multi‑year EPS estimates for WST (notable changes: FY2026 to $7.85 from $7.52, FY2027 to $8.79 from $8.51, and FY2028 to $10.29) and upgraded multiple quarter forecasts (Q1–Q4 2026 and Q1/Q4 2027). The firm keeps a “Strong‑Buy” rating — a coordinated set of upgrades that tends to support investor conviction and share demand. MarketBeat: West Pharmaceutical Services
• Neutral Sentiment: These revisions largely align with West’s own FY2026 guidance range (7.85–8.20 EPS), so part of the move may reflect confirmation of management direction rather than a surprise beat. Analysts’ models can change and represent expectations, not guarantees.

West Pharmaceutical Services Price Performance

Shares of NYSE:WST opened at $245.92 on Friday. West Pharmaceutical Services has a twelve month low of $187.43 and a twelve month high of $322.34. The company has a current ratio of 3.02, a quick ratio of 2.34 and a debt-to-equity ratio of 0.06. The company has a market cap of $17.71 billion, a PE ratio of 36.22, a price-to-earnings-growth ratio of 2.61 and a beta of 1.17. The company’s 50 day moving average is $253.72 and its 200 day moving average is $262.14.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, February 12th. The medical instruments supplier reported $2.04 EPS for the quarter, beating the consensus estimate of $1.83 by $0.21. The business had revenue of $805.00 million during the quarter, compared to analysts’ expectations of $795.70 million. West Pharmaceutical Services had a net margin of 16.06% and a return on equity of 17.90%. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.82 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. On average, sell-side analysts forecast that West Pharmaceutical Services will post 6.62 EPS for the current year.

West Pharmaceutical Services Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 6th. Shareholders of record on Wednesday, April 29th will be given a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 0.4%. The ex-dividend date is Wednesday, April 29th. West Pharmaceutical Services’s dividend payout ratio is currently 12.96%.

West Pharmaceutical Services announced that its Board of Directors has approved a share repurchase program on Tuesday, February 17th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical instruments supplier to reacquire up to 5.6% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.